The high transforming potential of constitutively activated Rho specific guanine nucleotide exchange factors (RhoGEFs) suggests an important role for the RhoGEF family members in oncogenic transformation. Consistent with this, BCR and LARG are already known to be contributing partners to chromosomal rearrangements that are associated with specific human leukemias (CML and MLL respectively). The Dbs oncogene encodes a RhoGEF that has potent transforming activity in both fibroblasts and human breast epithelial cells. We have determined that the transforming activity and intracellular localization of Dbs is regulated by an NH2-terminal Sec14 homology lipid binding domain, which is also found in several other family members (Kalirin, Dbl, Trio, UNC-73).
The aim of this proposal is to determine the molecular mechanism of Sec14 domain-mediated regulation of Dbs transforming activity. Using a homology model of this domain, in combination with liposome binding assays, we will identify mutations that completely disrupt lipid binding by this domain. We will then use these mutants to determine the role of lipid binding by the Sec14 domain in the regulation of proto-Dbs subcellular localization and transforming activity. Additionally, we will test if the Sec14 domain of Dbs can directly bind to its PH domain, and investigate the respective contributions of the Sec14 domain-mediated lipid binding, and PH domain binding, to Dbs transformation. Finally, we will use an immunofluorescence approach to visualize and compare spatio-specific RhoA activation by proto and onco-Dbs proteins. If our working model for Sec14 domain-mediated Dbs regulation is correct, this could establish a new paradigm for RhoGEF regulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32CA113049-01
Application #
6885510
Study Section
Special Emphasis Panel (ZRG1-F09 (20))
Program Officer
Lohrey, Nancy
Project Start
2005-03-15
Project End
2007-03-14
Budget Start
2005-03-15
Budget End
2006-03-14
Support Year
1
Fiscal Year
2005
Total Cost
$49,928
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
623946217
City
Newark
State
NJ
Country
United States
Zip Code
07107
Ingle, James N (2013) Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet 58:306-12
Kostenko, Elena V; Olabisi, Oyenike O; Sahay, Sutapa et al. (2006) Ccpg1, a novel scaffold protein that regulates the activity of the Rho guanine nucleotide exchange factor Dbs. Mol Cell Biol 26:8964-75
Olabisi, Oyenike O; Mahon, Gwendolyn M; Kostenko, Elena V et al. (2006) Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res 66:6250-7